Content
December 2024, Volume 42, Issue 12
- 1301-1315 Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning
by Paul Crosland & Deborah A. Marshall & Seyed Hossein Hosseini & Nicholas Ho & Catherine Vacher & Adam Skinner & Kim-Huong Nguyen & Frank Iorfino & Sebastian Rosenberg & Yun Ju Christine Song & Apostolos Tsiachristas & Kristen Tran & Jo-An Occhipinti & Ian B. Hickie - 1317-1327 MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial
by Ash Bullement & Mark Edmondson-Jones & Patricia Guyot & Nicky J. Welton & Gianluca Baio & Matthew Stevenson & Nicholas R. Latimer - 1329-1343 Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review
by Ippazio Cosimo Antonazzo & Giorgia Gribaudo & Adriano Vecchia & Pietro Ferrara & Alexandra Piraino & Paolo Angelo Cortesi & Lorenzo Giovanni Mantovani - 1345-1357 Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
by Meiyu Wu & Jing Ma & Sini Li & Shuxia Qin & Chongqing Tan & Ouyang Xie & Andong Li & Aaron G. Lim & Xiaomin Wan - 1359-1371 Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care
by Amy Gye & Richard Abreu Lourenco & Stephen Goodall - 1373-1394 Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
by Yankier Pijeira Perez & Dyfrig A. Hughes - 1395-1412 An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?
by Nicholas R. Latimer & Kurt Taylor & Anthony J. Hatswell & Sophia Ho & Gabriel Okorogheye & Clara Chen & Inkyu Kim & John Borrill & David Bertwistle - 1413-1425 Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter?
by Mihir Gandhi & Ravindran Kanesvaran & Mohamad Farid Bin Harunal Rashid & Dawn Qingqing Chong & Wen-Yee Chay & Rachel Lee-Yin Tan & Richard Norman & Madeleine T. King & Nan Luo
November 2024, Volume 42, Issue 11
- 1177-1179 Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective
by Keith Cooper & Emma Maund & Marcia Tomie Takahashi & Jonathan Shepherd - 1181-1196 Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling
by Kurt Taylor & Nicholas R. Latimer & Thomas Douglas & Anthony J. Hatswell & Sophia Ho & Gabriel Okorogheye & John Borril & Clara Chen & Inkyu Kim & David Bertwistle - 1197-1208 Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)
by Jeff Round & Erin Kirwin & Sasha Katwyk & Christopher McCabe - 1209-1236 Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses
by Ewan M. Tomeny & Thomas Hampton & Phuong Bich Tran & Laura Rosu & Mphatso D. Phiri & Kathryn A. Haigh & Jasper Nidoi & Tom Wingfield & Eve Worrall - 1237-1239 Delaying Oral Anticoagulants: A False Economy?
by Brendan Collins & Gregory Y. H. Lip - 1241-1253 Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation
by Ryan J. Mulholland & Giorgio Ciminata & Terry J. Quinn & Kevin G. Pollock & Steven Lister & Claudia Geue - 1255-1266 Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling
by Johanna Lister & Suzy Paisley & Christopher Carroll & Paul Tappenden - 1267-1277 Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study
by Cameron Morgan & Cam Donaldson & Emily Lancsar & Stavros Petrou & Lazaros Andronis - 1279-1286 Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program
by Snigdha Gulati & Mohak Gupta & TingTing Yan & Sneha Yelamanchili & Lucy Qinghua Xu & Tina Bharani & Ali Naji & Divyansh Agarwal - 1287-1300 Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee
by Zachary Tirrell & Alicia Norman & Martin Hoyle & Sean Lybrand & Bonny Parkinson
October 2024, Volume 42, Issue 10
- 1065-1072 Proxy Preferences and the Values of Children’s Health States
by Daniel M. Hausman - 1073-1090 Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know
by Nicholas R. Latimer & Mark J. Rutherford - 1091-1110 Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer
by Shikha Sharma & Niamh Carey & David McConnell & Maeve Lowery & Jacintha O’Sullivan & Laura McCullagh - 1111-1125 Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model
by Yawen Jiang & Jiaxin Wen & Jiatong Sun & Yuelong Shu - 1127-1144 Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework
by R. Douglas Scott & Steven D. Culler & James Baggs & Sujan C. Reddy & Kara Jacobs Slifka & Shelley S. Magill & Sophia V. Kazakova & John A. Jernigan & Richard E. Nelson & Robert E. Rosenman & Philip R. Wandschneider - 1145-1159 Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England
by Pamela Gongora-Salazar & Rafael Perera & Oliver Rivero-Arias & Apostolos Tsiachristas - 1161-1175 A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist
by Jemimah Ride & Ilias Goranitis & Yan Meng & Christine LaBond & Emily Lancsar
September 2024, Volume 42, Issue 9
- 913-917 NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective
by Najmeh Moradi & Nicole O’Connor & Katie H. Thomson & Hosein Shabaninejad & Tumi Sotire & Madeleine Still & Cristina Fernandez-Garcia & Sheila A. Wallace & Oleta Williams & Luke Vale & Gurdeep S. Sagoo - 919-928 Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation
by David Glynn & Vijay S. Gc & Karl Claxton & Chris Littlewood & Claire Rothery - 929-953 Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data
by Lisa A. Jong & Xinyu Li & Sajad Emamipour & Sjoukje Werf & Maarten J. Postma & Peter R. Dijk & Talitha L. Feenstra - 955-1002 A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models
by Andreas Freitag & Grammati Sarri & An Ta & Laura Gurskyte & Dasha Cherepanov & Luis G. Hernandez - 1003-1016 A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies
by Paul Tappenden & Orla Hardiman & Sun-Hong Kwon & Mon Mon-Yee & Miriam Galvin & Christopher McDermott - 1017-1028 Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
by Ni Gao & Helen A. Dakin & Rury R. Holman & Lee-Ling Lim & José Leal & Philip Clarke - 1029-1045 Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia
by Andrew J. Sutton & Daniel S. Lupu & Stephen P. Bergin & Thomas L. Holland & Staci A. McAdams & Sanjeet S. Dadwal & Khoi Nguyen & Frederick S. Nolte & Gabriel Tremblay & Bradley A. Perkins - 1047-1063 Estimating an EQ-5D-Y-3L Value Set for Brazil
by Caique Melo Espirito Santo & Gisela Cristiane Miyamoto & Verônica Souza Santos & Ângela Jornada Ben & Aureliano Paolo Finch & Bram Roudijk & Fabianna Resende Jesus-Moraleida & Airton Tetelbom Stein & Marisa Santos & Tiê Parma Yamato
August 2024, Volume 42, Issue 8
- 823-827 Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?
by Salah Ghabri - 829-832 Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective
by Mirre Scholte & Bram Ramaekers & Evangelos Danopoulos & Sabine E. Grimm & Andrea Fernandez Coves & Xiaoyu Tian & Thomas Debray & Jiongyu Chen & Lisa Stirk & Rachel Croft & Manuela Joore & Nigel Armstrong - 833-842 A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health
by Matthew P. Hamilton & Caroline Gao & Glen Wiesner & Kate M. Filia & Jana M. Menssink & Petra Plencnerova & David G. Baker & Patrick D. McGorry & Alexandra Parker & Jonathan Karnon & Sue M. Cotton & Cathrine Mihalopoulos - 843-863 A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses
by Ramesh Lamsal & E. Ann Yeh & Eleanor Pullenayegum & Wendy J. Ungar - 865-877 A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries
by Ery Setiawan & Sarah A. Cassidy-Seyoum & Kamala Thriemer & Natalie Carvalho & Angela Devine - 879-894 Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision
by Anne Bruijn & Mats Don & Saskia Knies & Werner Brouwer & Vivian Reckers-Droog - 895-909 Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries
by Laura Panattoni & Mairead Kearney & Natalie Land & Thomas Flottemesch & Patrick Sullivan & Melissa Kirker & Murtuza Bharmal & Brett Hauber - 911-911 Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries
by Laura Panattoni & Mairead Kearney & Natalie Land & Thomas Flottemesch & Patrick Sullivan & Melissa Kirker & Murtuza Bharmal & Brett Hauber
July 2024, Volume 42, Issue 7
- 715-719 Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling
by Isaac Corro Ramos & Talitha Feenstra & Salah Ghabri & Maiwenn Al - 721-735 Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure
by Joseph Alvin Ramos Santos & Robert Grant & Gian Luca Di Tanna - 737-749 Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature
by Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies - 751-765 Cost-of-Illness of Skin Cancer: A Systematic Review
by Annick Meertens & Laura Coile & Tijs Iseghem & Lieve Brochez & Nick Verhaeghe & Isabelle Hoorens - 767-782 Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations
by Muchandifunga Trust Muchadeyi & Karla Hernandez-Villafuerte & Gian Luca Tanna & Rachel D. Eckford & Yan Feng & Michela Meregaglia & Tessa Peasgood & Stavros Petrou & Jasper Ubels & Michael Schlander - 783-795 Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results
by Yanara Marks & Jeffrey S. Hoch & Anna Heath & Petros Pechlivanoglou - 797-810 A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations
by Junfeng Wang & Xavier Pouwels & Bram Ramaekers & Geert Frederix & Chris Lieshout & Rudolf Hoogenveen & Xinyu Li & G. Ardine Wit & Manuela Joore & Hendrik Koffijberg & Anoukh Giessen & Saskia Knies & Talitha Feenstra - 811-822 Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
by Takao Takeshima & Fumihiko Sakai & Xinyu Wang & Kentaro Yamato & Yoshitsugu Kojima & Yilong Zhang & Craig Bennison & Martijn J. H. G. Simons
June 2024, Volume 42, Issue 6
- 611-614 Market Transparency in Medicine Pricing: Pathways to Fair Pricing
by João L. Carapinha - 615-618 Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
by Bradley M. Sugden & Sabine E. Grimm & Robert Wolff & Nigel Armstrong & Thomas Otten & Teebah Abu-Zahra & Mark Perry & Mubarak Patel & Jiongyu Chen & Caro Noake & Manuela Joore & Willem J. A. Witlox - 619-631 Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
by Tobias Sydendal Grand & Shijie Ren & James Hall & Daniel Oudin Åström & Stephane Regnier & Praveen Thokala - 633-647 Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
by Clazinus Veijer & Marinus H. Hulst & Benjamin Friedrichson & Maarten J. Postma & Antoinette D.I. Asselt - 649-661 Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study
by Olu Onyimadu & Nerys M. Astbury & Felix Achana & Stavros Petrou & Mara Violato - 663-678 Developing a Program Costs Checklist of Digital Health Interventions: A Scoping Review and Empirical Case Study
by Zareen Abbas Khan & Kristian Kidholm & Sindre Andre Pedersen & Silje Marie Haga & Filip Drozd & Thea Sundrehagen & Ellen Olavesen & Vidar Halsteinli - 679-691 Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
by Anna Kenseth & Dominika Kantorova & Mikyung Kelly Seo & Eline Aas & John Cairns & David Kerr & Hanne Askautrud & Jørn Evert Jacobsen - 693-714 Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States
by William L. Herring & Meghan E. Gallagher & Nirmish Shah & KC Morse & Deirdre Mladsi & Olivia M. Dong & Anjulika Chawla & Jennifer W. Leiding & Lixin Zhang & Clark Paramore & Biree Andemariam
May 2024, Volume 42, Issue 5
- 475-478 Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap
by Erik Landfeldt & Hera Sandhu - 479-486 Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators
by Anna Heath & Gianluca Baio & Ioanna Manolopoulou & Nicky J. Welton - 487-506 Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments
by Jen-Yu Amy Chang & James B. Chilcott & Nicholas R. Latimer - 507-526 Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review
by Billingsley Kaambwa & Taylor-Jade Woods & Andrea Natsky & Norma Bulamu & Christine Mpundu-Kaambwa & Kelly A. Loffler & Alexander Sweetman & Peter G. Catcheside & Amy C. Reynolds & Robert Adams & Danny J. Eckert - 527-568 Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review
by Angie Raad & Maria Rizzo & Katherine Appiah & Isabella Kearns & Luis Hernandez - 569-582 Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
by Shih-Wen Lin & Sheila Shapouri & Hélène Parisé & Eric Bercaw & Mei Wu & Eunice Kim & Matthew Matasar - 583-603 Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary
by Anna Nikl & Mathieu F. Janssen & Balázs Jenei & Valentin Brodszky & Fanni Rencz - 605-606 Comment on: A Framework for the Fair Pricing of Medicines
by Zaheer-Ud-Din Babar - 607-609 Reply to Comment on “A Framework for Fair Pricing of Medicines”
by Mike Paulden
April 2024, Volume 42, Issue 4
- 363-371 A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework
by Natalia Kunst & Emily A. Burger & Veerle M. H. Coupé & Karen M. Kuntz & Eline Aas - 373-392 Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review
by Clara Marquina & Jedidiah I Morton & Melanie Lloyd & Dina Abushanab & Yeji Baek & Tamrat Abebe & Adam Livori & Padam Dahal & Gerald F. Watts & Zanfina Ademi - 393-407 An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada
by Diedron Lewis & William W. L. Wong & Joseph Lipscomb & Susan Horton - 409-418 Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
by Dong-Won Kang & Li Wang & Nicholas J. Short & Alessandra Ferrajoli & Yucai Wang & Shouhao Zhou & Chan Shen - 419-434 Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
by Zakile A. Mfumbilwa & Martijn J. H. G. Simons & Bram Ramaekers & Valesca P. Retèl & Joanne M. Mankor & Harry J. M. Groen & Joachim G. J. V. Aerts & Manuela Joore & Janneke A. Wilschut & Veerle M. H. Coupé - 435-446 The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life
by Cate Bailey & Martin Howell & Rakhee Raghunandan & Kim Dalziel & Kirsten Howard & Brendan Mulhern & Stavros Petrou & Donna Rowen & Amber Salisbury & Rosalie Viney & Emily Lancsar & Nancy Devlin - 447-461 Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
by Anita J. Brogan & Ashley E. Davis & Claire E. Mellott & Jeremy Fraysse & Aimee A. Metzner & Alan K. Oglesby - 463-473 The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective
by Assegid Hellebo & Andre P. Kengne & Zanfina Ademi & Olufunke Alaba
March 2024, Volume 42, Issue 3
- 249-252 Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement
by Stephanie Harvard - 253-259 A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments
by T. Joseph Mattingly - 261-273 Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial
by Junwen Zhou & Claire Williams & Mi Jun Keng & Runguo Wu & Borislava Mihaylova - 275-299 Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review
by Lucinda J. Teoh & Salomey Kellett & Dipesh E. Patel & Mario Cortina-Borja & Ameenat Lola Solebo & Jugnoo S. Rahi - 301-318 Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review
by Ana Helena Perea-Bello & Marta Trapero-Bertran & Christian Dürsteler - 319-328 Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
by Antal Zemplenyi & Jim Leonard & Michael J. DiStefano & Kelly E. Anderson & Garth C. Wright & Nicholas D. Mendola & Kavita Nair & R. Brett McQueen - 329-341 Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study
by Jason Gordon & Maria Gheorghe & Cale Harrison & Ryan Miller & James Dennis & Lotte Steuten & Simon Goldenberg & Sumanth Gandra & Amer Al-Taie - 343-362 Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force
by Edward Henry & Hareth Al-Janabi & Werner Brouwer & John Cullinan & Lidia Engel & Susan Griffin & Claire Hulme & Pritaporn Kingkaew & Andrew Lloyd & Nalin Payakachat & Becky Pennington & Luz María Peña-Longobardo & Lisa A. Prosser & Koonal Shah & Wendy J. Ungar & Thomas Wilkinson & Eve Wittenberg
February 2024, Volume 42, Issue 2
- 133-136 Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
by Giovany Orozco-Leal & Eugenie Evelynne Johnson & Sedighe Hosseinijebeli & Tomos Robinson & Tara Homer & Claire H. Eastaugh & Catherine Richmond & Louise Tanner & Nick Meader & Ryan Kenny & Sheila A. Wallace & Stephen Rice - 137-144 Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
by Daniel Gladwell & Oriana Ciani & Adam Parnaby & Stephen Palmer - 145-164 A Framework for the Fair Pricing of Medicines
by Mike Paulden - 165-176 Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments
by Alex J. Turner & Cormac Sammon & Nick Latimer & Blythe Adamson & Brennan Beal & Vivek Subbiah & Keith R. Abrams & Joshua Ray - 177-198 Systematic Review of the Relative Social Value of Child and Adult Health
by Tessa Peasgood & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Marcus Sellars & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Kirsten Howard & Emily Lancsar & Stavros Petrou & Julie Ratcliffe & Rosalie Viney & Germaine Wong & Richard Norman & Cam Donaldson - 199-217 A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects
by Ramesh Lamsal & E. Ann Yeh & Eleanor Pullenayegum & Wendy J. Ungar - 219-229 Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study
by Javier Mar & Oliver Ibarrondo & Carlo Delfin S. Estadilla & Nico Stollenwerk & Fernando Antoñanzas & Rubén Blasco-Aguado & Igor Larrañaga & Joseba Bidaurrazaga & Maíra Aguiar - 231-247 Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
by Christopher W. Yee & Michael J. Harvey & Yiqiao Xin & Noam Y. Kirson
July 2024, Volume 42, Issue 2
- 183-185 Advancing Methods to Measure and Reward Healthcare Innovation
by Richard Chapman & Richard Xie - 187-197 The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment
by Frederick McElwee & Anthony Newall - 199-210 Incorporating Real Option Value in Valuing Innovation: A Way Forward
by Meng Li & Louis P. Garrison - 211-224 Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework
by Askal Ayalew Ali & Amit Kulkarni & Sandipan Bhattacharjee & Vakaramoko Diaby
January 2024, Volume 42, Issue 1
- 5-9 Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective
by Diarmuid Coughlan & Oluwatomi Arisa & Katie Thomson & Ge Yu & Fiona Pearson & Ashleigh Kernohan & Sonia Garcia Gonzalez-Moral & Sheila Wallace & Stephen Rice - 11-18 The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations
by Daniel Hill-McManus - 19-40 A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus
by Marina Antoniou & Céu Mateus & Bruce Hollingsworth & Andrew Titman - 41-68 Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis
by Melissa Lannon & Taylor Duda & Alexander Mastrolonardo & Ellissa Huang & Amanda Martyniuk & Forough Farrokhyar & Feng Xie & Mohit Bhandari & Suneil K. Kalia & Sunjay Sharma - 69-90 Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada
by Aneeka Hafeez & Lauren E. Cipriano & Richard B. Kim & Gregory S. Zaric & Ute I. Schwarz & Sisira Sarma - 91-107 Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
by Jedidiah I. Morton & Clara Marquina & Melanie Lloyd & Gerald F. Watts & Sophia Zoungas & Danny Liew & Zanfina Ademi - 109-116 Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer
by Anthony J. Hatswell & Mohammad A. Chaudhary & Giles Monnickendam & Alejandro Moreno-Koehler & Katie Frampton & James W. Shaw & John R. Penrod & Rachael Lawrance - 117-131 Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
by Daniel Tobias Michaeli & Thomas Michaeli
June 2024, Volume 42, Issue 1
- 3-8 Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children
by Wendy J. Ungar & Michael Herdman - 9-37 Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review
by Christine Mpundu-Kaambwa & Norma B. Bulamu & Lauren Lines & Gang Chen & David G. T. Whitehurst & Kim Dalziel & Nancy Devlin & Julie Ratcliffe - 39-55 Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study
by Renee Jones & Rachel O’Loughlin & Xiuqin Xiong & Mina Bahrampour & Nancy Devlin & Harriet Hiscock & Gang Chen & Brendan Mulhern & Kim Dalziel - 57-77 Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression
by Rachel O’Loughlin & Renee Jones & Gang Chen & Brendan Mulhern & Harriet Hiscock & Nancy Devlin & Kim Dalziel - 79-79 Correction: Comparing the Psychometric Performance of Generic Paediatric Health‑Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression
by Rachel O’Loughlin & Renee Jones & Gang Chen & Brendan Mulhern & Harriet Hiscock & Nancy Devlin & Kim Dalziel - 81-94 Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis
by Mina Bahrampour & Renee Jones & Kim Dalziel & Nancy Devlin & Brendan Mulhern - 95-111 A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data
by Mina Bahrampour & Nancy Devlin & Renee Jones & Kim Dalziel & Brendan Mulhern - 113-128 An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L
by Diana Khanna & Jyoti Khadka & Christine Mpundu-Kaambwa & Gang Chen & Kim Dalziel & Nancy Devlin & Julie Ratcliffe - 129-145 Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds
by Alexander Heusden & Oliver Rivero-Arias & Michael Herdman & Harriet Hiscock & Nancy Devlin & Kim Dalziel - 147-161 Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2–4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL)
by Xiuqin Xiong & Natalie Carvalho & Li Huang & Gang Chen & Renee Jones & Nancy Devlin & Brendan Mulhern & Kim Dalziel - 163-179 The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions
by Cate Bailey & Kim Dalziel & Renee Jones & Harriet Hiscock & Nancy J. Devlin & Tessa Peasgood
December 2023, Volume 41, Issue 12
- 1553-1555 The Carer QALY Trap and Altruism in Economic Evaluations
by J. Mick Tilford & Aygul Tarlan - 1557-1561 Modelling Spillover Effects on Informal Carers: The Carer QALY Trap
by David J. Mott & Hannah Schirrmacher & Hareth Al-Janabi & Sophie Guest & Becky Pennington & Nicolas Scheuer & Koonal K. Shah & Chris Skedgel - 1563-1588 Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies
by Deborah A. Marshall & Brittany Gerber & Diane L. Lorenzetti & Karen V. MacDonald & Riley Jewel Bohach & Gillian R. Currie - 1589-1601 Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations
by Kumar Mukherjee & Necdet B. Gunsoy & Rita M. Kristy & Joseph C. Cappelleri & Jessica Roydhouse & Judith J. Stephenson & David J. Vanness & Sujith Ramachandran & Nneka C. Onwudiwe & Sri Ram Pentakota & Helene Karcher & Gian Luca Di Tanna - 1603-1615 Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens
by David Teigen & Robert O. Opoka & Phillip Kasirye & Catherine Nabaggala & Heather A. Hume & Bjørn Blomberg & Chandy C. John & Russell E. Ware & Bjarne Robberstad - 1617-1627 Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
by Boshen Jiao - 1629-1639 De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
by Peter Gal & Gyorgyi Feldmajer & Margarida Augusto & Ray Gani & Emma Hook & Ash Bullement & Zoe Philips & Inger Smith - 1641-1655 Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
by Michaela Carla Barbier & Alicia Fengler & Esther Pardo & Arjun Bhadhuri & Niklaus Meier & Oliver Gautschi - 1657-1673 Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom
by Jason Gordon & Maria Gheorghe & Simon Goldenberg & Ryan Miller & James Dennis & Amer Al-Taie
November 2023, Volume 41, Issue 11
- 1403-1413 Conducting Trial-Based Economic Evaluations Using R: A Tutorial
by Ângela Jornada Ben & Johanna M. Dongen & Mohamed El Alili & Jonas L. Esser & Hana Marie Broulíková & Judith E. Bosmans - 1415-1435 Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review
by Katja C. Heinz & Charlotte Beaudart & Damon Willems & Isabell Wiethoff & Mickaël Hiligsmann - 1437-1452 Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)
by Nick Jovanoski & Seye Abogunrin & Danilo Di Maio & Rossella Belleli & Pollyanna Hudson & Sneha Bhadti & Libby G. Jones - 1453-1467 Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies
by Xuejing Jin & Wanxian Liang & Lining Zhang & Shihuan Cao & Lujia Yang & Feng Xie - 1469-1514 A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
by Henrik Vitus Bering Laursen & Emmelie Ploug Jørgensen & Peter Vestergaard & Lars Holger Ehlers - 1515-1524 EQ-5D-5L Value Set for Slovenia
by Valentina Prevolnik Rupel & Marko Ogorevc - 1525-1537 Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia
by Preston Ngo & Deme Karikios & David Goldsbury & Stephen Wade & Zarnie Lwin & Brett G. M. Hughes & Kwun M. Fong & Karen Canfell & Marianne Weber - 1539-1550 Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model
by Kathrin Pahmeier & Christian Speckemeier & Silke Neusser & Jürgen Wasem & Janine Biermann-Stallwitz - 1551-1551 Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Thomas Otten & Rob Riemsma & Ben Wijnen & Nigel Armstrong & Lisa Stirk & Caroline Gordon & Bram Ramaekers & Jos Kleijnen & Manuela Joore & Sabine Grimm
October 2023, Volume 41, Issue 10
- 1165-1174 Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
by Nancy J. Devlin & Tianxin Pan & Mark Sculpher & Mark Jit & Elly Stolk & Donna Rowen & Barend Hout & Richard Norman - 1175-1182 An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year
by Jonathan D. Campbell & Melanie D. Whittington & Steven D. Pearson - 1183-1203 Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review
by Martijn J. Oude Wolcherink & Carina M. Behr & Xavier G. L. V. Pouwels & Carine J. M. Doggen & Hendrik Koffijberg - 1205-1228 Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
by Judith Dams & Johann-Jacob Zapp & Hans-Helmut König - 1229-1248 Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review
by Mussab Fagery & Hadi A. Khorshidi & Stephen Q. Wong & Martin Vu & Maarten IJzerman - 1249-1262 Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
by Xinyu Li & Rudolf Hoogenveen & Mohamed El Alili & Saskia Knies & Junfeng Wang & Joline W. J. Beulens & Petra J. M. Elders & Giel Nijpels & Anoukh Giessen & Talitha L. Feenstra - 1263-1274 Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients
by Xinyu Wang & Kentaro Yamato & Yoshitsugu Kojima & Josef J. Paris & Elisabeth F. P. Peterse & Martijn J. H. G. Simons & Craig Bennison - 1275-1286 Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses
by Noga Epstein & Tzahit Simon-Tuval & Yakir Berchenko - 1287-1388 Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA
by Michael Falk Hvidberg & Mónica Hernández Alava - 1389-1402 Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries
by Sebastian Neumann-Böhme & Iryna Sabat & Carolin Brinkmann & Arthur E. Attema & Tom Stargardt & Jonas Schreyögg & Werner Brouwer
September 2023, Volume 41, Issue 9
- 1027-1030 Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs
by Werner Brouwer & Pieter Baal - 1031-1050 Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review
by Marieke Krol & Nikkie Hosseinnia & Werner Brouwer & Leona Hakkaart Roijen - 1051-1064 Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics
by Beata Koń & Michał Jakubczyk - 1065-1077 Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis
by Boshen Jiao & Anirban Basu - 1079-1091 Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway
by Johan A. Liseth Hansen & Thomas Fast & Knut Reidar Wangen - 1093-1101 Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries
by Paul Hanly & Marta Ortega Ortega & Alison Pearce & Marianna Camargo Cancela & Isabelle Soerjomataram & Linda Sharp - 1103-1115 Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects
by Werner Brouwer & Kaya Verbooy & Renske Hoefman & Job Exel - 1117-1136 Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort
by Syed Afroz Keramat & Rubayyat Hashmi & Bolaji Samson Aregbeshola & Tracy Comans - 1137-1149 Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses
by Saskia Groot & Irene Santi & Pieter Bakx & Bram Wouterse & Pieter Baal - 1151-1164 Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy
by David D. Kim
August 2023, Volume 41, Issue 8
- 843-844 Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey
by Alper Tuna Güven - 845-856 How Much Better is Faster? Value Adjustments for Health-Improvement Sequences
by F. Reed Johnson & Juan Marcos Gonzalez & John J. Sheehan & Shelby D. Reed - 857-867 Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Willem Witlox & Sabine Grimm & Jeremy Howick & Nigel Armstrong & Charlotte Ahmadu & Kevin McDermott & Thomas Otten & Caro Noake & Robert Wolff & Manuela Joore - 869-911 Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review
by Hans Van Remoortel & Hans Scheers & Bert Avau & Jørgen Georgsen & Susan Nahirniak & Nadine Shehata & Simon J. Stanworth & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 913-943 Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review
by Charles Okafor & Joshua Byrnes & Simon Stewart & Paul Scuffham & Clifford Afoakwah - 945-980 A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
by Lara Chayab & Natalia Konstantelos & Natasha B. Leighl & Mina Tadrous & William W. L. Wong - 981-997 Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
by Marianne Luyendijk & Agnes Jager & Sanne M. Buijs & Sabine Siesling & Carin A. Uyl-de Groot & Hedwig M. Blommestein - 999-1010 Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
by Maria Jesus Rodríguez-Nieto & Esteban Cano-Jiménez & Ana D. Romero Ortiz & Ana Villar & Marta Morros & Alba Ramon & Silvia Armengol - 1011-1025 Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers
by Aurelie Meunier & Louise Longworth & Manuel Gomes & Sreeram Ramagopalan & Louis P. Garrison & Sanjay Popat
July 2023, Volume 41, Issue 7
- 733-740 Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance
by Stephanie Harvard & Eric Winsberg - 741-750 Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Giovany Orozco Leal & Nigel Armstrong & Ashleigh Kernohan & Charlotte Ahmadu & Diarmuid Coughlan & Kevin McDermott & Steven Duffy & Susan O’Meara & Tomos Robinson & Luke Vale & Jos Kleijnen - 751-769 Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature
by Daniel D. Joyce & Vidit Sharma & Stephen B. Williams - 771-785 Economic Impact of Insufficient and Disturbed Sleep in the Workplace
by Danielle R. Glick & Samuel A. Abariga & Irine Thomas & Andrea G. Shipper & Brian C. Gunia & Michael A. Grandner & Elliot Rosenberg & Stella E. Hines & Vincent Capaldi & Jacob Collen & Emerson M. Wickwire - 787-802 Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward
by Sergio Torres-Rueda & Fern Terris-Prestholt & Mitzy Gafos & Pitchaya Peach Indravudh & Rebecca Giddings & Fiammetta Bozzani & Matthew Quaife & Lusine Ghazaryan & Carlyn Mann & Connie Osborne & Matthew Kavanagh & Peter Godfrey-Faussett & Graham Medley & Shelly Malhotra - 803-818 Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review
by Gillian R. Currie & Brittany Gerber & Diane Lorenzetti & Karen MacDonald & Susanne M. Benseler & Francois P. Bernier & Kym M. Boycott & K. Vanessa Carias & Bettina Hamelin & Robin Z. Hayeems & Claire LeBlanc & Marinka Twilt & Gijs Rooijen & Durhane Wong-Rieger & Rae S. M. Yeung & Deborah A. Marshall - 819-830 Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
by Mickaël Hiligsmann & Stuart S. Silverman & Andrea J. Singer & Leny Pearman & Jake Mathew & Yamei Wang & John Caminis & Jean-Yves Reginster - 831-841 Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions
by James Love-Koh & Paul Schneider & Simon McNamara & Tim Doran & Nils Gutacker
June 2023, Volume 41, Issue 6
- 607-617 The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice
by Bram Wouterse & Pieter Baal & Matthijs Versteegh & Werner Brouwer - 619-632 Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
by Thomas Michael Otten & Sabine E. Grimm & Bram Ramaekers & Manuela A. Joore - 633-650 Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review
by Olena Mandrik & Anne I. Hahn & James W. F. Catto & Ann G. Zauber & Marcus Cumberbatch & James Chilcott - 651-673 Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review
by Yared Belete Belay & Lidia Engel & Yong Yi Lee & Ngoc Le & Cathrine Mihalopoulos - 675-692 Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review
by Sean P. Gavan & Stuart J. Wright & Fiona Thistlethwaite & Katherine Payne - 693-707 Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models
by Rebecca Giddings & Pitchaya Indravudh & Graham F. Medley & Fiammetta Bozzani & Mitzy Gafos & Shelly Malhotra & Fern Terris-Prestholt & Sergio Torres-Rueda & Matthew Quaife - 709-718 Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
by Prajakta P. Masurkar & Haluk Damgacioglu & Ashish A. Deshmukh & Meghana V. Trivedi - 719-732 Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031
by Dina Abushanab & Clara Marquina & Jedidiah I. Morton & Daoud Al-Badriyeh & Melanie Lloyd & Dianna J. Magliano & Danny Liew & Zanfina Ademi
May 2023, Volume 41, Issue 5
- 467-480 Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review
by Fiammetta M. Bozzani & Fern Terris-Prestholt & Matthew Quaife & Mitzy Gafos & Pitchaya P. Indravudh & Rebecca Giddings & Graham F. Medley & Shelly Malhotra & Sergio Torres-Rueda - 481-497 Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
by Kris Doggen & Albert Jan van Hoek & Jeroen Luyten - 499-527 Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review
by Emily R. Strouphauer & Olivia J. Morris & Keaton J. Soileau & Andrew D. Wiese & Troy Quast & Wayne K. Goodman & Sameer A. Sheth & Katharine D. Wojcik & Andrew G. Guzick & Eric A. Storch - 529-545 HTA Barriers for Conditional Approval Drugs
by Mackenzie Mills - 547-559 Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
by Junwen Zhou & Runguo Wu & Claire Williams & Jonathan Emberson & Christina Reith & Anthony Keech & John Robson & Kenneth Wilkinson & Jane Armitage & Alastair Gray & John Simes & Colin Baigent & Borislava Mihaylova - 561-572 How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes
by Valeska Hofbauer-Milan & Stefan Fetzer & Christian Hagist - 573-587 The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight)
by Jacqueline Roseleur & David A. Gonzalez-Chica & Gillian Harvey & Nigel P. Stocks & Jonathan Karnon - 589-604 Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
by Taku Kobayashi & Masato Hoshi & Akira Yuasa & Shoko Arai & Mitsunobu Ikeda & Hiroyuki Matsuda & Seok-Won Kim & Toshifumi Hibi - 605-605 Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
by Hardik Goswami & Adnan Alsumali & Yiling Jiang & Matthias Schindler & Elizabeth R. Duke & Joshua Cohen & Andrew Briggs & Amy Puenpatom
April 2023, Volume 41, Issue 4
- 339-351 Modelling the Cost-Effectiveness of Diagnostic Tests
by Tristan Snowsill - 353-361 Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Mohamed N. M. T. Al Khayat & Nigel Armstrong & Jeremy Howick & Susan O’Meara & Pawel Posadzki & Steve Ryder & Charlotte Ahmadu & Stefan R. A. Konings & Maarten J. Postma & Steven Duffy & Robert F. Wolff & Antoinette D. I. Asselt - 363-391 Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
by Nannan Li & Charlotte Beaudart & Jane A. Cauley & Steven W. Ing & Nancy E. Lane & Jean-Yves Reginster & Stuart Silverman & Andrea J. Singer & Mickaël Hiligsmann - 393-393 Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
by Nannan Li & Charlotte Beaudart & Jane A. Cauley & Steven W. Ing & Nancy E. Lane & Jean‑Yves Reginster & Stuart Silverman & Andrea J. Singer & Mickaël Hiligsmann - 395-411 Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations
by Carina M. Behr & Martijn J. Oude Wolcherink & Maarten J. IJzerman & Rozemarijn Vliegenthart & Hendrik Koffijberg - 413-425 Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario
by John J. Kim & Wasem Alsabbagh & William W. L. Wong - 427-438 The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia
by Richard Norman & Brendan Mulhern & Emily Lancsar & Paula Lorgelly & Julie Ratcliffe & Deborah Street & Rosalie Viney - 439-455 Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study
by Mengmeng Zhang & Yun Bao & Yi Yang & Melissa Kimber & Mitchell Levine & Feng Xie - 457-466 Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis
by Praveen Thokala & Pann Ei Hnynn Si & Monica Hernandez Alava & Alessandro Sasso & Thilo Schaufler & Marco Soro & James Fotheringham
March 2023, Volume 41, Issue 3
- 227-237 Living Health Technology Assessment: Issues, Challenges and Opportunities
by Praveen Thokala & Tushar Srivastava & Robert Smith & Shijie Ren & Melanie D. Whittington & Jamie Elvidge & Ruth Wong & Lesley Uttley - 239-251 Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Antoinette D. I. Asselt & Nigel Armstrong & Merel Kimman & Andrea Peeters & Kevin McDermott & Lisa Stirk & Charlotte Ahmadu & Tim M. Govers & Frank Hoentjen & Manuela A. Joore & Sabine E. Grimm - 253-273 Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review
by Marie-Hélène Blanchet Zumofen & Jeff Frimpter & Svenn Alexander Hansen - 275-293 Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review
by Erik Landfeldt & Sophia Abner & Astrid Pechmann & Thomas Sejersen & Hugh J. McMillan & Hanns Lochmüller & Janbernd Kirschner - 295-306 Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment
by Yuqiong Lu & Zhanjing Dai & Feng Chang & Li Wang & Jiafang He & Penghua Shi & Haitao Zhang & Yun Lu